4
MARKET OVERVIEW
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN EUROPE HEALTHCARE INDUSTRY
5.2.4
TRENDS IN EUROPE PHARMA INDUSTRY
5.5.1
AVERAGE SELLING PRICE OF KEY PLAYERS, BY END-USE INDUSTRY,
5.5.2
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
5.5.3
AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
5.6
KEY CONFERENCES & EVENTS, 2025-2026
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.7.1
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.8
INVESTMENT AND FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFF ON EUROPE HUMAN MICROBIOME MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1.1
WHOLE-GENOME SEQUENCING
6.1.2
16S RNA SEQUENCING METHOD
6.1.3
NANOPORE SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
METATRANSCRIPTOMICS
6.3
ADJACENT TECHNOLOGIES
6.7
IMPACT OF AI/GEN AI ON EUROPE HUMAN MICROBIOME MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED HUMAN MICROBIOME WORKFLOWS
6.7.3
CASE STUDIES OF AI ADOPTION IN EUROPE HUMAN MICROBIOME MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED MICROBIOME ANALYTICS SOLUTIONS
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE HUMAN MICROBIOME MARKET, BY PRODUCT, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY PRODUCTS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
9.2
HUMAN MICROBIOME DRUGS
9.3
HUMAN MICROBIOME SUPPLEMENTS
9.4
MICROBIOME DIAGNOSTICS
10
EUROPE HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY DRUGS & SUPPLEMENTS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
10.2
BACTERIAL CONSORTIA TRANSPLANT (BCT)/FECAL MICROBIOTA TRANSPLANT (FMT)
10.3
LIVE BACTERIA PRODUCTS
11
EUROPE HUMAN MICROBIOME MARKET, BY DISEASE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DISEASES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
11.3
GASTROINTESTINAL DISEASES
11.4
ENDOCRINE & METABOLIC DISORDERS
12
EUROPE HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY ROUTES OF ADMINISTRATION, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
12.2
ORAL ROUTE OF ADMINISTRATION
12.3
RECTAL ROUTE OF ADMINISTRATION
13
EUROPE HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY SERVICES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
13.2
STRAIN DEVELOPMENT & OPTIMIZATION
13.3
FERMENTATION & DOWNSTREAM PROCESSING
13.4
FORMULATION & FILL/FINISH
14
EUROPE HUMAN MICROBIOME MARKET, BY END USER, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DEMAND PATTERNS, MARKET POTENTIAL ACROSS CUSTOMERS
14.3
LONG-TERM CARE FACILITIES
15
EUROPE HUMAN MICROBIOME MARKET, BY COUNTRY, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY COUNTRIES
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
16.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN (JANUARY 2022 – NOVEMBER 2025)
16.3
REVENUE ANALYSIS, 2020–2024
16.4
MARKET SHARE ANALYSIS,
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
COUNTRY FOOTPRINT
16.5.5.3
PRODUCT FOOTPRINT
16.5.5.5
DISEASE FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
16.7
COMPETITIVE SCENARIO
16.7.1
PRODUCT/SERVICE LAUNCHES
16.8
BRAND/PRODUCT COMPARISON
16.8.2
OPTIBIOTIX HEALTH PLC
16.9
COMPANY VALUATION AND FINANCIAL METRICS
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE EUROPE HUMAN MICROBIOME MARKET LANDSCAPE
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.1.3.2
STRATEGIC CHOICES
17.1.1.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.2
OPTIBIOTIX HEALTH PLC
17.1.2.1
BUSINESS OVERVIEW
17.1.2.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.2.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.2.3.2
STRATEGIC CHOICES
17.1.2.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.3.1
BUSINESS OVERVIEW
17.1.3.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.3.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.3.3.2
STRATEGIC CHOICES
17.1.3.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.4.1
BUSINESS OVERVIEW
17.1.4.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.4.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.4.3.2
STRATEGIC CHOICES
17.1.4.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.5
ACTIAL FARMACEUTICA SRL
17.1.5.1
BUSINESS OVERVIEW
17.1.5.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.5.3.1
KEY STRENGTHS/RIGHT TO WIN
17.1.5.3.2
STRATEGIC CHOICES
17.1.5.3.3
WEAKNESSES/COMPETITIVE THREATS
17.1.6
INFANT BACTERIAL THERAPEUTICS AB
17.1.6.1
BUSINESS OVERVIEW
17.1.6.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.6.3
RECENT DEVELOPMENTS
17.1.7.1
BUSINESS OVERVIEW
17.1.7.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.7.3
RECENT DEVELOPMENTS
17.1.8.1
BUSINESS OVERVIEW
17.1.8.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.8.3
RECENT DEVELOPMENTS
17.1.9.1
BUSINESS OVERVIEW
17.1.9.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.9.3
RECENT DEVELOPMENTS
17.1.10.1
BUSINESS OVERVIEW
17.1.10.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.1.10.3
RECENT DEVELOPMENTS
18.1.1.1
KEY SOURCES OF SECONDARY DATA
18.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
18.1.2.1
BREAKDOWN OF PRIMARIES
18.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
18.2
MARKET SIZE ESTIMATION
18.2.1
EUROPE HUMAN MICROBIOME MARKET SIZE ESTIMATION,
18.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
18.2.1.2
MNM REPOSITORY ANALYSIS
18.2.1.3
SECONDARY ANALYSIS
18.2.1.4
PRIMARY RESEARCH
18.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
18.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
18.3
MARKET GROWTH RATE PROJECTIONS
18.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Europe Human Microbiome Market